CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11 | +450.0% | 250 | +733.3% | 0.01% | +600.0% |
| Q2 2023 | $2 | -92.6% | 30 | -95.0% | 0.00% | -94.4% |
| Q1 2023 | $27 | -50.9% | 600 | -55.6% | 0.02% | -52.6% |
| Q4 2022 | $55 | -99.8% | 1,350 | +145.5% | 0.04% | +100.0% |
| Q1 2022 | $35,000 | +29.6% | 550 | +57.1% | 0.02% | +26.7% |
| Q4 2021 | $27,000 | +92.9% | 350 | +180.0% | 0.02% | +87.5% |
| Q3 2021 | $14,000 | -30.0% | 125 | 0.0% | 0.01% | -33.3% |
| Q2 2021 | $20,000 | – | 125 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |